

References

- ¹ Langer, I, *Journal of Physiology*, 1967, **190**, 41P.
- ² Beumer, H M, *Lancet*, 1967, **2**, 993.
- ³ McNeil, R S, *Lancet*, 1964, **2**, 1101.
- ⁴ Whelan, R F, and Young, I M, *British Journal of Pharmacology*, 1953, **8**, 98.
- ⁵ Young, I M, *Journal of Physiology*, 1957, **137**, 374.
- ⁶ Lambertsen, C J, in *Handbook of Physiology*, section 3, vol 1, ed W O Fenn and H Rahn, p 551. Washington, American Physiological Society, 1964.
- ⁷ Leitch, A G, *et al*, *British Medical Journal*, 1976, **1**, 365.
- ⁸ Rebeck, A S, Jones, N L, and Campbell, E J M, *Clinical Science*, 1972, **43**, 861.
- ⁹ Matthews, A W, and Howell, J B L, *Clinical Science and Molecular Medicine*, 1975, **49**, 57.
- ¹⁰ McNeil, R S, and Ingram, C G, *American Journal of Cardiology*, 1966, **18**, 473.
- ¹¹ Macdonald, A G, Ingram, C G, and McNeill, R S, *British Journal of Anaesthesia*, 1967, **39**, 919.
- ¹² Richardson, P S, and Sterling, G M, *British Medical Journal*, 1969, **3**, 143.
- ¹³ Tattersfield, A E, Leaver, D G, and Pride, N B, *Journal of Applied Physiology*, 1973, **35**, 613.
- ¹⁴ Gayraud, P, *et al*, *Thorax*, 1975, **30**, 657.
- ¹⁵ Barrett, A M, and Cullum, V A, *British Journal of Pharmacology*, 1968, **34**, 43.
- ¹⁶ Read, D J C, *Australasian Annals of Medicine*, 1967, **16**, 20.
- ¹⁷ Shand, D G, Nickolls, E M, and Oates, J A, *Clinical Pharmacology and Therapeutics*, 1970, **2**, 112.
- ¹⁸ Matthews, A W, and Howell, J B L, *Clinical Science and Molecular Medicine*, 1976, **50**, 199.
- ¹⁹ Purves, M J, and Biscoe, T J, in *Arterial Chemoreceptors*, ed P W Torrance. Oxford, Blackwell, 1968.
- ²⁰ Read, D J C, and Leigh, J, *Journal of Applied Physiology*, 1967, **23**, 53.
- ²¹ Lefrancois, R, *et al*, *Respiration Physiology*, 1972, **14**, 296.
- ²² Myers, M G, *et al*, *Journal of Pharmacology and Experimental Therapeutics*, 1975, **192**, 327.
- ²³ Young, R, Growdon, J H, and Shahani, B T, *New England Journal of Medicine*, 1975, **293**, 950.
- ²⁴ Bakke, O M, *et al*, *British Journal of Pharmacology*, 1974, **51**, 148P.
- ²⁵ Stone, D J, Kelts, H, and Samortin, T, *American Review of Respiratory Disease*, 1971, **103**, 503.
- ²⁶ Nordstrom, L A, Macdonald, F, and Gobel, F L, *Chest*, 1975, **67**, 287.

SHORT REPORTS

Persistent intestinal protein loss after measles

Measles is one of the commonest precipitating factors in kwashiorkor.¹ There is appreciable intestinal protein loss during acute measles infection in underweight children with diarrhoea,^{2,3} and I have investigated the possibility that if this persists it might cause kwashiorkor.

Patients, methods, and results


Six children with persistent diarrhoea after measles were studied. The history of measles was confirmed either by documentation during the acute illness or by post-measles skin staining on examination. None had diarrhoea before the onset of measles. Their ages ranged from 20 months to 9 years (mean age 38 months). All weighed less than 80% of the Harvard standard growth curve (mean value $59 \pm \text{SD } 10\%$). Their mean serum albumin level was $23 \pm 4 \text{ g/l}$. Three of the children had developed oedema since the acute illness. Stool culture grew no important pathogens. One child had ova of *Schistosoma mansoni* in the stool. Controls were five children who had recovered from measles but were being reinvestigated after intestinal protein loss had been found during acute measles, as described previously.² Their mean age was 30 ± 13 months, and their mean weight $81 \pm 15\%$ of the Harvard standard growth curve.

⁵⁹Fe-labelled iron dextran (⁵⁹Fe) was used to measure intestinal protein loss. A dose of $0.1 \mu\text{Ci/kg}$ was injected intravenously, and all stools over the next three days were collected. Plasma was sampled daily. The faecal clearance of ⁵⁹Fe thus calculated correlated closely with plasma protein loss into the gut.⁴ With the assumption that albumin is cleared similarly to ⁵⁹Fe,⁴ the absolute albumin loss was estimated from the faecal ⁵⁹Fe clearance and calculated total intravascular albumin pool. The mean faecal clearance in the patients with post-measles diarrhoea was $6.5 \pm 4.2\%$ of the plasma volume daily. This was significantly higher than in the controls, whose clearance was $2.0 \pm 0.9\%$ of the plasma volume daily ($t = 2.6$; $P < 0.05$). Those with oedema had a greater clearance than those without oedema (see figure). The mean absolute albumin loss was significantly ($P < 0.05$) greater in the patients with post-measles diarrhoea ($0.9 \pm 0.7 \text{ g/day}$) than in the controls ($0.4 \pm 0.3 \text{ g/day}$).

Discussion

The patients with post-measles diarrhoea continued to lose protein in the stool two to four weeks after measles, having a similar ⁵⁹Fe clearance to that found in acute measles² and a significantly higher clearance than children who had recovered from measles.

Kwashiorkor developed in the three patients with the highest protein losses. The mean absolute albumin loss in all the patients with post-measles diarrhoea was almost 1 g daily—an important loss, since their mean total intravascular albumin pool was only $13 \pm 4 \text{ g}$. The mean loss of 0.4 g albumin daily in the controls was from a mean total intravascular albumin pool of $24 \pm 7 \text{ g}$. Shukry *et al*⁵ found that children with kwashiorkor lost little protein in the stool in the absence



Clearance of ⁵⁹Fe-labelled iron dextran in six patients with post-measles diarrhoea and five controls ($t = 2.6$; $P < 0.05$).

of diarrhoea, and our unpublished results confirm this. Thus the protein loss in the patients with post-measles diarrhoea was related to the diarrhoea and not to the poor state of nutrition.

We do not know whether measles virus has any specific role in the syndrome of post-measles diarrhoea. Superinfection by bacteria or fungi in the large bowel or small bowel is a possible explanation, since secondary infections after measles are common in other tissues. Possibly underweight children with diarrhoea from any cause may lose similar amounts of protein to the children in this study.

I thank Dr Norman Veall for the ⁵⁹Fe-labelled iron dextran, and Dr H Whittle and Dr B M Greenwood for their help.

- ¹ Ogbeide, M I, *West African Medical Journal*, 1971, **20**, 313.
- ² Dossetor, J F B, and Whittle, H C, *British Medical Journal*, 1975, **2**, 592.
- ³ Axton, J H M, *British Medical Journal*, 1975, **3**, 79.
- ⁴ Jarnum, S, *et al*, *Gastroenterology*, 1968, **55**, 229.
- ⁵ Shukry, A S, *et al*, *Journal of Tropical Medicine and Hygiene*, 1965, **68**, 269.

Department of Paediatrics, Ahmadu Bello University, Zaria, Nigeria

J F B DOSSETOR, DCH, MRCP, lecturer in paediatrics